CSIMarket
 


Humanigen Inc  (HGEN)
Other Ticker:  
 

Cumulative Humanigen Inc's Working Capital Ratio for Trailing Twelve Months Period

HGEN's Working Capital Ratio for Trailing Twelve Months Period and Current Assets, Current Liabilities growth


Select the Comparisons : Select the Ratio:

HGEN Working Capital Ratio for Trailing Twelve Months Period

(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
Y / Y Current Liabilities Growth -25.13 % -18.23 % 11.17 % 53.02 % 33.66 %
Y / Y Current Assets Growth -92.94 % -84.35 % -66.76 % -59.42 % -27.87 %
Working Capital Ratio for Trailing Twelve Months Period 0.35 0.56 0.74 0.94 1.32
Total Ranking # 4042 # 4463 # 4045 # 4480 # 3896
Seq. Current Liabilities Growth -5.16 % -26.44 % -0.78 % 8.16 % 3.57 %
Seq. Current Assets Growth -54.74 % -57.09 % -47.57 % -30.71 % 0.37 %


Working Capital Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Mar 31 2023
On the trailing twelve months basis Despite year on year decrease in Humanigen Inc's average Current Liabilities to $53 millions, Working Capital Ratio for Trailing Twelve Months Period to 0.35 below company average Working Capital Ratio for Trailing Twelve Months Period.
Working Capital Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry 538 other companies have achieved higher Working Capital Ratio for Trailing Twelve Months Period than Humanigen Inc. While overall ranking remained unchanged compare to previous quarter at no. .

What is Working Capital Ratio?
More about HGEN
Working Capital Ratio HGEN in the most recent quarter
Working Capital Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 539
Sector # 1099
S&P 500 # 4245


Working Capital Ratio for Trailing Twelve Months Period Statistics
High Average Low
5.89 1.55 0.06
(Sep. 30, 2014)   (Mar 31 2020)




Companies with similar average Working Capital Ratio for Trailing Twelve Months Period for 12 months ending Mar 31 2023, within Major Pharmaceutical Preparations Industry Working Capital Ratio for Trailing Twelve Months Period
Innovation Pharmaceuticals Inc   0.94 
Ensysce Biosciences Inc   0.90 
Abbvie inc   0.89 
Soligenix inc   0.89 
Gelesis Holdings Inc   0.85 
Phasebio Pharmaceuticals Inc.  0.84 
Janone Inc   0.84 
Renovaro Inc   0.83 
Protokinetix Incorporated  0.83 
180 Life Sciences Corp  0.81 
Skye Bioscience Inc   0.81 
Procaps Group S a   0.81 
Ainos Inc   0.77 
Allarity Therapeutics Inc   0.75 
Sunwin Stevia International Inc.  0.74 
Panbela Therapeutics Inc   0.74 
Aditxt Inc   0.70 
First Wave Biopharma Inc   0.70 
Lucy Scientific Discovery Inc   0.67 
Acer Therapeutics Inc   0.66 
Regenerx Biopharmaceuticals inc   0.66 
International Stem Cell Corporation  0.64 
Agile Therapeutics Inc  0.64 
China Pharma Holdings Inc   0.62 
Baudax Bio Inc   0.59 
Paxmedica Inc   0.57 
Therapeuticsmd Inc   0.53 
Humanigen Inc  0.53 
Takeda Pharmaceutical Company Limited  0.53 
Athersys Inc  0.52 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com